Merck's HIV treatment meets main goal of two late-stage studies

investing.com • 19/12/2024 - 11:58 AM

Merck's Experimental Drug Combination for HIV-1 Treatment

(Reuters) – Merck (NS:PROR) announced on Thursday that its experimental drug combination aimed at treating certain adults with HIV-1 infection successfully met the primary objectives of two late-stage studies.

Comments (0)

Cancel

Greed and Fear Index

Note: The data is for reference only.

Extreme Greed

Merck's HIV treatment meets main goal of two late-stage studies

Merck's Experimental Drug Combination for HIV-1 Treatment

Comments (0)

Cancel

Greed and Fear Index

Submit your comment

Thank you!

Report this comment

Thank you!

Currency